Pharmaceuticals ( ISIS -3.1% ) discloses that it earned an $18M milestone payment from development partner Biogen Idec ( BIIB -1.1% ) by virtue of dosing the first infant in the ENDEAR Phase 3 clinical trial evaluating ISIS-SMNrx as
expect relatively flat royalty payments from Tysabri due to emerging competition from oral multiple sclerosis drugs like Biogen Idec ’s Tecfidera. We currently don’t forecast material future cash flows for an expanded indication of Tysabri in
The FDA approves Biogen Idec 's (NASDAQ: BIIB ) Plegridy ( peginterferon beta-1a ) for the treatment of patients with relapsing forms of multiple sclerosis (MS). It is
NEW YORK, AUG 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older...
Aug 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling...
directors, one of whom--Phillip Sharp--won the Nobel Prize in 1993 for his work with DNA and also cofounded Biogen (now Biogen Idec ). Although Sharp and Maraganore clearly lack independence from management, we think Alnylam's other seven
Katz – Vice President and Director, Brookings Institution Ed Dondero – Director of Real Estate and Planning at Biogen Idec John Fry – President, Drexel University Presentation Rick Howe [Starts Abruptly] Investor Day 2014, on the 10th
infants with spinal muscular atrophy (SMA). This event will trigger an $18M milestone payment from development partner Biogen (NASDAQ: BIIB ). The primary endpoint of the 110-infant study is survival or permanent ventilation. 1 comment!
in Copaxone sales this quarter, which ultimately reduces the market opportunity for Momenta as new oral drugs, like Biogen Idec ’s Tecfidera, alter the competitive landscape of the multiple sclerosis market. Additionally, Teva has now shifted
Morrissey (former president of R&D at Exelixis) replaced longtime CEO George Scangos, who left the company to lead Biogen Idec . Morrissey has made his mark by restructuring the company away from its discovery platform model to focus primarily